Antitumor Necrosis Factor (TNF-a) Antibodies in the Treatment of Renal Cell Cancer

REFERENCES

• Godley P. A., Taylor M. Renal cell carcinoma. Curr. Opin. Oncol. 2001; 13(3)199–203
   PubMed Web of Science ®Google Scholar
• Chow W. H., Devesa S. S., Warren J. L., Fraumeni J. F. Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999; 281(17)1628–1631
   Google Scholar
• Lam J., Breda A., Belldegrun A. S., Figlin R. A. Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J. Clin. Oncol. 2006; 24(35)5565–5575
   PubMed Web of Science ®Google Scholar
• Campbell S. C., Flanigan R. C., Clark J. I. Nephrectomy in metastatic renal cell carcinoma. Curr. Treat. Options Oncol. 2003; 4(5)363–372
   PubMedGoogle Scholar
• Amato R. J. Chemotherapy for renal cell carcinoma. Semin. Oncol. 2000; 27(2)177–186
   PubMed Web of Science ®Google Scholar
• Milowsky M. I., Nanus D. M. Chemotherapeutic strategies for renal cell carcinoma. Urol. Clin. North. Am. 2003; 30(3)601–609
   PubMed Web of Science ®Google Scholar
• Amato R. J. Thalidomide therapy for renal cell carcinoma. Crit. Rev. Oncol. Hematol. 2003; 27: S59–S65, (Suppl. 46)
   Google Scholar
• Pyrhonen S., Salminen E., Ruutu M., Lehtonen T., Nurmi M., et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol. 1999; 17(9)2859–2867
   PubMed Web of Science ®Google Scholar
• Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999; 353(9146)14–17
   Google Scholar
• Minasian L. M., Motzer R. J., Gluck L., Mazumdar M., Vlamis V., Krown S. E. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J. Clin. Oncol. 1993; 11(7)1368–1375
   PubMed Web of Science ®Google Scholar
• Escudier B. B., Szczylik C., Eisen T., Stadler W. M., Schwartz B., Shan M., Bukowski R. M. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 2005, (Abstr. 4510)
   PubMedGoogle Scholar
• Motzer R. J., Rini B. I., Michaelson M. D., Redman B. G., Hudes G. R., Wilding G., Bukowski R. M., George D. J., Kim S. T., Baum C. M. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 2005, (Abstr. 4508)
   Google Scholar
• Motzer R. J., Michaelson M. D., Redman B. G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006; 24(1)16–2
   PubMed Web of Science ®Google Scholar
• Balkwill F. Tumor necrosis factor or tumor promoting factor?. Cytokine Growth Factor Rev. 2002; 13(2)135–141
   PubMed Web of Science ®Google Scholar
• Locksley R. M., Killeen N., Lenardo M. J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104(4)487–501
   PubMed Web of Science ®Google Scholar
• Szlosarek P. W., Balkwill F. R. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 2003; 4(9)565–573
   PubMed Web of Science ®Google Scholar
• Mizutani Y., Bonavida B., Nio Y., Yoshida O. Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization. J. Urol. 1994; 151(6)1697–1702
   PubMed Web of Science ®Google Scholar
• Tselepis C., Perry I., Dawson C., et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 2002; 21(39)6071–81
   PubMed Web of Science ®Google Scholar
• Wu S., Boyer C. M., Whitaker R. S., et al. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res. 1993; 53(8)1939–1944
   PubMed Web of Science ®Google Scholar
• Gaiotti D., Chung J., Iglesias M., et al. Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway. Mol. Carcinog. 2000; 27(2)97–109
   PubMed Web of Science ®Google Scholar
• Moore R. J., Owens D. M., Stamp G., et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med. 1999; 5(7)828–831
   PubMed Web of Science ®Google Scholar
• Eisen T., Boshoff C., Mak I., et al. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. J. Cancer 2000; 82(4)812–817
   PubMed Web of Science ®Google Scholar
• Stebbing J., Benson C., Eisen T., et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br. J. Cancer 2001; 85(7)953–958
   PubMed Web of Science ®Google Scholar
• Daliani D. D., Papandreou C. N., Thall P. F., et al. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 2002; 95(4)758–765
   PubMed Web of Science ®Google Scholar
• Escudier B., Lassau N., Couanet D., et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann. Oncol. 2002; 13(7)1029–1035
   PubMed Web of Science ®Google Scholar
• Motzer R. J., Berg W., Ginsberg M., et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J. Clin. Oncol. 2002; 20(1)302–306
   PubMed Web of Science ®Google Scholar
• Minor D. R., Monroe D., Damico L. A., Meng G., Suryadevara U., Elias L. A phase II study of thalidomide in advanced metastatic renal cell carcinoma. Invest. New Drugs 2002; 20(4)389–393
   PubMed Web of Science ®Google Scholar
• Novik Y., Dutcher J. P., Larkin M. Phase II study of thalidomide (T) in advanced refractory metastatic renal cell carcinoma (MRCC): A single institution experience. Proc. Am. Soc. Clin. Oncol. 2001; 265a, (Abstr. 1057)
   Google Scholar
• Li Z., Amato R., Papandreou C. N. Phase II study of thalidomide for patients with metastatic renal cell cancer (MRCC) progressing after interleukin-2 (IL-2)-based therapy (Rx). Proc. Am. Soc. Clin. Oncol. 2001; 180a, (Abstr. 717)
   Google Scholar
• Ching L. M., Xu Z. F., Gummer B. H., Palmer B. D., Joseph W. R., Baguley B. C. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br. J. Cancer 1995; 72(2)339–343
   PubMed Web of Science ®Google Scholar
• Knight D. M., Trinh H., Le J., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 1993; 30(16)1443–1453
   PubMed Web of Science ®Google Scholar
• Scallon B. J., Moore M. A., Trinh H., Knight D. M., Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7(3)251–259
   PubMed Web of Science ®Google Scholar
• Maini R., St Clair E. W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354(9194)1932–1939
   PubMed Web of Science ®Google Scholar
• Maisey N., Hall K., Lee C., Timotheadou E., Ahern R., Eisen T., Gore M. Infliximab: A Phase II Trial Of The Tumour Necrosis Factor (TNF) Monoclonal Antibody In Patients With Advanced Renal Cell Cancer (RCC). Proc. Am. Soc. Clin. Oncol. 2004, (Abstr. 4514)
   Web of Science ®Google Scholar
• Weidmann E., Bergmann L., Stock J., Kirsten R., Mitrou P. S. Rapid cytokine release in cancer patients treated with interleukin-2. J. Immunother. 1992; 12(2)123–131
   PubMed Web of Science ®Google Scholar
• Lopez Hanninen E., Kirchner H., Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J. Urol. 1996; 155(1)19–25
   PubMed Web of Science ®Google Scholar
• Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer. 2004; 4(7)540–550
   PubMed Web of Science ®Google Scholar
• Mantovani A., Bottazzi B., Colotta F., Sozzani S., Ruco L. The origin and function of tumor-associated macrophages. Immunol. Today 1992; 13(7)265–270
   PubMedGoogle Scholar
• Conti I., Rollins B. J. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin. Cancer Biol. 2004; 14(3)149–154
   PubMed Web of Science ®Google Scholar